Curto A,
Albaladejo A, Alvarado A. Dental management of patients taking novel oral
anticoagulants (NOAs): Dabigatran. J Clin
Exp Dent. 2017;9(2):e289-93.
doi:10.4317/jced.53219
References
|
1. Falck-Ytter Y, Francis
CW, Johanson NA, Curley C, Dahl OE, Schulman S, et al. Prevention of VTE in
Orthopedic Surgery Patients: Antithrombotic Therapy and Prevention of
Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based
Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e278S-325S. PMid: 22315265 PMCid: 3278063 |
|
|
|
|
|
2. Laupacis A, Albers G,
Dalen J, Dunn MI, Jacobson AK, Singer DE. The Evolving Consensus.
Antithrombotic therapy in Atrial Fibrillation. Chest. 1998;114:579-89. PMid: 9822064 |
|
|
|
|
|
3. Lip GY, Mitchell SA,
Liu X, Liu LZ, Phatak H, Kachroo S, et al. Relative efficacy and safety of
non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation:
Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and
edoxaban in three patient subgroups. Int J Cardiol. 2016;204:88-94. |
|
|
|
|
|
4. Wallentin L, Yusuf S,
Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. Efficacy and safety of
dabigatran compared with warfarin at different levels of international
normalised ratio control for stroke prevention in atrial fibrillation: an
analysis of the RE-LY trial. Lancet. 2010;376:975-83. PMid: 20801496 |
|
|
|
|
|
5. Hohnloser SH, Oldgren
J, Yang S, Wallentin L, Ezekowitz M, Reilly P, et al. Myocardial ischemic
events in patients with atrial fibrillation treated with dabigatran or
warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation
Therapy) trial. Circulation. 2012;125:669-76. |
|
|
|
|
|
6. Clemens A, Peng S,
Brand S, Brueckmann M, Kansal A, Lim J, et al. Efficacy and
cost-effectiveness of dabigatran etexilate versus warfarin in atrial
fibrillation in different age subgroups. Am J Cardiol. 2014;114:849-55. |
|
|
|
|
|
7. Huntington JA, Baglin
TP. Targeting thrombin--rational drug design from natural mechanisms. Trends
Pharmacol Sci. 2003;24:589-95. |
|
|
|
|
|
8. Blech S, Ebner T,
Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of
the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos.
2008;36:386-99. |
|
|
|
|
|
9. Eriksson BI, Quinlan
DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral
direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet.
2009;48:1-22. |
|
|
|
|
|
10. Hu TY, Vaidya VR,
Asirvatham SJ. Reversing anticoagulant effects of novel oral anticoagulants:
role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk
Manag. 2016;12:35-44. |
|
|
|
|
|
11.
van Leent MW, Stevanović J, Jansman FG, Beinema MJ, Brouwers JR, Postma
MJ. Cost-Effectiveness of Dabigatran Compared to
Vitamin-K Antagonists for the Treatment of Deep Venous Thrombosis in the
Netherlands Using Real-World Data. PLoS One. 2015;10:e0135054. |
|
|
|
|
|
12.
Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Palareti G, et al. Questions and answers on the use of dabigatran and
perspectives on the use of other new oral anticoagulants in patients with
atrial fibrillation. A consensus document of the Italian Federation of
Thrombosis Centers (FCSA). Thromb Haemost. 2011;106:868-76. |
|
|
|
|
|
13. Cuker A, Siegal D.
Monitoring and reversal of direct oral anticoagulants. Hematology Am Soc
Hematol Educ Program. 2015;2015:117-24. |
|
|
|
|
|
14. Gosselin RC, Dwyre DM,
Dager WE. Measuring dabigatran concentrations using a chromogenic ecarin
clotting time assay. Ann Pharmacother. 2013;47:1635-40. |
|
|
|
|
|
15. Dager WE, Gosselin RC,
Kitchen S, Dwyre D. Dabigatran effects on the international normalized ratio,
activated partial thromboplastin time, thrombin time, and fibrinogen: a
multicenter, in vitro study. Ann Pharmacother. 2012;46:1627-36. |
|
|
|
|
|
16. Avecilla ST, Ferrell
C, Chandler WL, Reyes M. Plasma-diluted thrombin time to measure dabigatran
concentrations during dabigatran etexilate therapy. Am J Clin Pathol. 2012;137:572-4. |
|
|
|
|
|
17. Perry DJ, Noakes TJ,
Helliwell PS; British Dental Society. Guidelines for the management of
patients on oral anticoagulants requiring dental surgery. Br Dent J. 2007;203:389-93. |
|
|
|
|
|
18. O'Connell JE, Stassen
LF. New oral anticoagulants and their implications for dental patients. J Ir
Dent Assoc. 2014;60:137-43. |
|
|
|
|
|
19. Limdi NA, Limdi MA,
Cavallari L, Anderson AM, Crowley MR, Baird MF, et al. Warfarin dosing in
patients with impaired kidney function. Am J Kidney Dis. 2010;56:823-31. |
|
|
|
|
|
20. Healey
JS, Eikelboom
J, Douketis
J, Wallentin
L, Oldgren
J, Yang
S, et al. Periprocedural bleeding and thromboembolic events with
dabigatran compared with warfarin: results from the Randomized Evaluation of
Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation.
2012;126:343-8. |
|
|
|
|
|
21. Connolly SJ, Ezekowitz
MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin
in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51. |
|
|
|
|
|
22. Elad S, Marshall J,
Meyerowitz C, Connolly G. Novel anticoagulants: general overview and
practical considerations for dental practitioners. Oral Dis. 2016;22:23-32. |
|
|
|
|
|
23. Johnston S. A New
Generation of Antiplatelet, and Anticoagulant Medication and the Implications
for the Dental Surgeon. Dent Update. 2015;42:840-2. |
|
|
|
|
|
24. Scott A, Gibson J,
Crighton A. The management of dental patients taking new generation oral
anticoagulants. Prim Dent J. 2014;3:54-8. |
|
|
|
|
|
25. Tsolka P. Dental
Procedures in Patients with Atrial Fibrillation and New Oral Anticoagulants.
Arrhythm Electrophysiol Rev. 2014;3:85-9. |
|
|
|
|
|
26. Hong CH, Islam I.
Anti-Thrombotic Therapy: Implications for Invasive Outpatient Procedures in
Dentistry. J Blood Disorders Transf. 2013;4:166. |
|
|
|
|
|
27. van Diermen DE, van
der Waal I, Hoogstraten J. Management recommendations for invasive dental
treatment in patients using oral antithrombotic medication, including novel
oral anticoagulants. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;116:709-16. |
|
|
|
|
|
28. Spyropoulos AC,
Douketis JD. How I treat anticoagulated patients undergoing an elective
pro-cedure or surgery. Blood. 2012;120:2954-62. |
|
|
|
|
|
29. Crowther MA, Warkentin
TE. Bleeding risk and the management of bleeding complications in patients
undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood. 2008;111:4871-9. |
|
|
|
|
|
30. Breik O, Cheng A,
Sambrook P, Goss A. Protocol in managing oral surgical patients taking
dabigatran. Aust Dent J. 2014;59:296-301. |
|
|
|
|
|
31. Curtin C, Hayes JM,
Hayes J. Dental implications of new oral anticoagulants for atrial
fibrillation. Dent Update. 2014;41:526-8,530-1. |
|
|
|
|
|
32.
Bacci C, Maglione M, Favero L, Perini A, Di Lenarda R, Berengo M, et al. Management of dental extraction in patients
undergoing anticoagulant treatment. Results from a large, multicentre,
prospective, case–control study. Thromb Haemost. 2010;104:972-5. |
|
|
|
|
|
33. Breik O, Tadros R,
Devitt P. Thrombin inhibitors: surgical considerations and pharmacology. ANZ
J Surg. 2013;83:215-21. |
|
|
|
|
|
34. van Ryn J, Stangier J,
Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran
etexilate--a novel, reversible, oral direct thrombin inhibitor:
interpretation of coagulation assays and reversal of anticoagulant activity. Thromb
Haemost. 2010 Jun;103(6):1116-27. |
|
|
|
|
|
35. Crowther MA, Warkentin
TE. Managing bleeding in anticoagulated patients with a focus on novel
therapeutic agents. J Thromb Haemost. 2009;7:107-10. |
|
|
|
|
|
36. Davis C, Robertson C,
Shivakumar S, Lee M. Implications of Dabigatran, a direct thrombin inhibitor,
for oral surgery practice. J Can Dent Assoc. 2013;79:d74. |
|
|
|
|
|
37. Eikelboom JW,
Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of
bleeding with 2 doses of dabigatran compared with warfarin in older and
younger patients with atrial fibrillation: an analysis of the randomized
evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation.
2011;123:2363-72. |
|
|
|
|
|
38. Stangier J, Rathgen K,
Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and
tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor,
in healthy male subjects. Br J Clin Pharmacol. 2007;64:292-303. |
|
|
|
|
|
39. Firriolo FJ, Hupp WS.
Beyond warfarin: the new generation of oral anticoagulants and their
implications for the management of dental patients. Oral Surg Oral Med Oral
Pathol Oral Radiol. 2012;113:431-41. |
|
|
|
|
|
40. Hankey GJ, Eikelboom
JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation. 2011;123:1436-50. |
|